Will management provide updated guidance for the remainder of 2025, including R&D spend and operating expenses?

Answer

Based on the information released in the Business Wire announcement, there is no explicit statement that Stoke Therapeutics’ management will issue updated full‑year guidance—including specific targets for research‑and‑development (R&D) spend or operating expenses—for the remainder of 2025 during the upcoming webcast and conference call.

What the announcement does say

• The company will hold a webcast and conference call on Tuesday, August 12 2025 at 4:30 p.m. ET.
  
• The purpose of the call is to discuss “Second Quarter 2025 Business and Financial Updates.”
  
• The focus will likely include a review of Q2 results, progress on the lead investigational medicine (zorevunersen), and other operational highlights.

Implications for guidance

• In earnings‑related calls, companies often provide “financial updates” that can range from a simple recap of the quarter’s numbers to a broader outlook for the rest of the fiscal year.
  
• However, the wording in the press release does not mention “updated guidance,” “full‑year outlook,” “R&D expense guidance,” or “operating expense guidance.”
  
• Therefore, we cannot definitively say that management will supply a revised R&D or operating‑expense budget for 2025. The only thing we can state with confidence is that they will discuss the quarter’s performance; any additional forward‑looking guidance would be speculative at this point.

Bottom line

• Will management provide updated guidance for the remainder of 2025, including R&D spend and operating expenses?
  The announcement does not confirm that such guidance will be given. It only guarantees a discussion of Q2 2025 business and financial results. If guidance is provided, it will be disclosed during the call itself, but there is no guarantee based on the current information.
  

If you need a definitive answer, the best course of action is to listen to the August 12 webcast (or review the accompanying slide deck/press release that typically follows the call) where any forward‑looking guidance, if offered, will be clearly outlined.